Glycon Pharma 

Dopamine glycoconjugate that traverses the blood-brain barrier. And more…

OWNER

Amit Matta (See Profile)


Sector

Therapeutics

Stage

Prototyping, preclinical

Country

USA


Reversal and elimination of Parkinson’s symptoms in 3 different rodent model studies as well as a marmoset model study.

Very Long washout period vs. current therapies which may result in the reduction/elimination of On/Off fluctuations

No adverse events observed in the rodent model or marmoset model studies and no Levodopa Induced Dyskinesia, LID

Molecule facilitates dopamine to cross the Blood Brain Barrier with superior efficacy and no observed side effects

Potential applicability other dopamine deficient conditions - essential tremors, Huntington’s, addiction, PTSD, ADHD etc

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck

Under evaluation at least till: 21st February

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar